Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: Jul 1, 2025
Open Peer Review Period: Jul 2, 2025 - Aug 27, 2025
Date Accepted: Nov 25, 2025
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

MyPainPal, a Novel mHealth App to Improve Pain in Patients With Advanced Cancer: Single-Arm Pilot Study

Azizoddin DR, Hassett M, Anderson KAS, Kessler D, Wright AA, Gorra M, Kematick BS, Chua IS, Brandoff D, Lally K, Nabati L, MacIsaac S, Tulsky JA, Enzinger AC

MyPainPal, a Novel mHealth App to Improve Pain in Patients With Advanced Cancer: Single-Arm Pilot Study

JMIR Cancer 2025;11:e79942

DOI: 10.2196/79942

PMID: 41468579

PMCID: 12811039

MyPainPal: A single-arm pilot study of a novel mHealth application to improve pain in patients with advanced cancer

  • Desiree R Azizoddin; 
  • Michael Hassett; 
  • Kris-Ann S Anderson; 
  • Daniella Kessler; 
  • Alexi A Wright; 
  • Madeline Gorra; 
  • Benjamin S Kematick; 
  • Isaac S Chua; 
  • Douglas Brandoff; 
  • Kate Lally; 
  • Lida Nabati; 
  • Susan MacIsaac; 
  • James A Tulsky; 
  • Andrea C Enzinger

ABSTRACT

Background:

Advanced cancer patients often experience poorly managed pain.

Objective:

We evaluated the feasibility and acceptability of MyPainPal, a mobile health (mHealth) application that combines daily symptom and opioid-use surveys, algorithmic self-management support, psychoeducation, and clinician monitoring.

Methods:

This single-arm pilot study enrolled adults with advanced malignancies using opioids for moderate-to-severe pain from a major cancer center’s palliative care clinic. Participants used the app for 28 days; nurses monitored symptoms on a secure portal. Patients assessed usability and acceptability assessments. Semi-structured patient debriefing interviews explored app utilization, perceived impact, and optimization strategies.

Results:

Twenty participants (mean age 57[SD=12.3], 55% female, 80% White with mixed cancer types enrolled, used MyPainPal a median of 14 times (IQR:8,17), and completed 8 symptom surveys (IQR:5,14) reflecting 36% (SD:20%) of eligible (out-of-hospital) days on study. Participants found the app acceptable; mean system usability scale=78.3/100 (SD=16.2); 79% rated their overall satisfaction as ≥4/5. Twenty percent of surveys generated an alert, prompting nurse outreach. In response, five participants had symptom medications changed and two had medication errors corrected. Participants described reduced barriers to pain reporting and facilitated constructive interactions with care teams, and several noted it validated their pain experience, reduced opioid stigma, and promoted self-management. Patients recommended featuring educational resources more prominently, modifying symptom surveys, and introducing MyPainPal earlier in their pain trajectory.

Conclusions:

MyPainPal demonstrated feasibility, acceptability, and preliminary evidence of clinical impact. In response, the app is being adapted for a future efficacy study. Clinical Trial: NCT03717402


 Citation

Please cite as:

Azizoddin DR, Hassett M, Anderson KAS, Kessler D, Wright AA, Gorra M, Kematick BS, Chua IS, Brandoff D, Lally K, Nabati L, MacIsaac S, Tulsky JA, Enzinger AC

MyPainPal, a Novel mHealth App to Improve Pain in Patients With Advanced Cancer: Single-Arm Pilot Study

JMIR Cancer 2025;11:e79942

DOI: 10.2196/79942

PMID: 41468579

PMCID: 12811039

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.